Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Charalampos Theocharopoulos"'
Autor:
Ioannis-Alexios Koumprentziotis, Charalampos Theocharopoulos, Dimitra Foteinou, Erasmia Angeli, Amalia Anastasopoulou, Helen Gogas, Dimitrios C. Ziogas
Publikováno v:
Vaccines, Vol 12, Iss 1, p 54 (2024)
Immune checkpoints (ICs) are molecules implicated in the fine-tuning of immune response via co-inhibitory or co-stimulatory signals, and serve to secure minimized host damage. Targeting ICs with various therapeutic modalities, including checkpoint in
Externí odkaz:
https://doaj.org/article/d5ce8c95cb3348eb828196dd87d0b9df
Autor:
Dimitrios C. Ziogas, Dimitrios Mandellos, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Spyros Bouros, Paolo A. Ascierto, Helen Gogas
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
More than 40 tyrosine kinase inhibitors (TKIs) have received hematological or oncological indications over the past 20 years, following the approval of imatinib, and many others are currently being tested in clinical and preclinical level. Beyond the
Externí odkaz:
https://doaj.org/article/c8a87ccea5b445639a20a774446e9a22
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Antibody–drug conjugates (ADCs) are designed to manipulate the toxic efficacy of specific chemotherapeutic compounds, employing the high affinity of antibody-mediated delivery so as to drive them selectively to target cancer cells. These immunoconj
Externí odkaz:
https://doaj.org/article/83e7799b61ea4b7899b2aaa30d330a93
Autor:
Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Michael Samarkos, Helen Gogas, Dimitrios C. Ziogas
Publikováno v:
Vaccines, Vol 9, Iss 10, p 1111 (2021)
In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of
Externí odkaz:
https://doaj.org/article/ba7cd38f77ea4666a0fb97b6efb606d7
Autor:
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, John Haanen, Helen Gogas
Publikováno v:
Cancer treatment reviews. 113
Marching into the second decade after the approval of ipilimumab, it is clear that immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis of melanoma. Although the current edge is already high, with a 4-year OS% of 77.9% for adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45761d343a2900934a301e363a90349d
https://pubmed.ncbi.nlm.nih.gov/36542945
https://pubmed.ncbi.nlm.nih.gov/36542945
Autor:
Charalampos Theocharopoulos
Publikováno v:
Acta Europeana Systemica. 8:327-338
The human body is regarded as a system of high complexity, not only because it is consisted of millions of interrelated and interdependent functional units -the cells-, but because it is also an evolving system. It changes over time, initially to ach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8ac5d89a2122b29970fe562086241a1
https://doi.org/10.14428/aes.v8i1.56513
https://doi.org/10.14428/aes.v8i1.56513
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Antibody–drug conjugates (ADCs) are designed to manipulate the toxic efficacy of specific chemotherapeutic compounds, employing the high affinity of antibody-mediated delivery so as to drive them selectively to target cancer cells. These immunoconj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3526fee33b1c7cae1f7100f4f65374db
http://europepmc.org/articles/PMC7543133
http://europepmc.org/articles/PMC7543133
Autor:
Michael Samarkos, Dimitrios C. Ziogas, Charalampos Theocharopoulos, Helen Gogas, Panagiotis-Petros Lialios
Publikováno v:
Vaccines, Vol 9, Iss 1111, p 1111 (2021)
Vaccines
Vaccines
In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a81b82634e70f0f496cf98df30c34c5f
https://doi.org/10.3390/vaccines9101111
https://doi.org/10.3390/vaccines9101111
Autor:
Legaki E; Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Greece (Evangelia Legaki, Tilemachos Koutouratsas, Charalampos Theocharopoulos, Vivian Lagkada, Maria Gazouli)., Koutouratsas T; Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Greece (Evangelia Legaki, Tilemachos Koutouratsas, Charalampos Theocharopoulos, Vivian Lagkada, Maria Gazouli)., Theocharopoulos C; Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Greece (Evangelia Legaki, Tilemachos Koutouratsas, Charalampos Theocharopoulos, Vivian Lagkada, Maria Gazouli)., Lagkada V; Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Greece (Evangelia Legaki, Tilemachos Koutouratsas, Charalampos Theocharopoulos, Vivian Lagkada, Maria Gazouli)., Gazouli M; Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Greece (Evangelia Legaki, Tilemachos Koutouratsas, Charalampos Theocharopoulos, Vivian Lagkada, Maria Gazouli).
Publikováno v:
Annals of gastroenterology [Ann Gastroenterol] 2024 Jan-Feb; Vol. 37 (1), pp. 64-70. Date of Electronic Publication: 2023 Dec 20.